Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance

Charles River Laboratories Intl. IncTrade
Consumer Staples Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Consumer Staples Select Sector SPDR Fund trades at $85.08. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.

CRLXLP
Market Cap
$13.46B
Sector
Health
52-Week High
$282.00$90.00
52-Week Low
$145.57$75.61
Enterprise Value
$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Consumer Staples Select Sector SPDR Fund

XLP trades at $85.04, up 0.11% with a neutral technical signal. Analyst consensus is unanimously bullish with a 100% buy rating. The fund offers a defensive play in consumer staples, with recent news highlighting sector resilience amid market shifts toward quality stocks.

Outlook remains positive given strong analyst support and defensive positioning, though limited fundamental data and sector concentration risks warrant monitoring. The dividend yield adds income appeal, but reliance on broad market sentiment for consumer staples drives volatility exposure.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Consumer Staples Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.

Read more on XLP